基因流与Acuitas合作开发针对年龄相关疾病的基因疗法传递系统. Genflow partners with Acuitas to develop gene therapy delivery systems for age-related diseases.

总部位于英国的生物技术公司Genflow Biosciences与Acuitas Therapeutics合作开发针对年龄相关疾病的基因疗法传递系统. UK-based biotech Genflow Biosciences has partnered with Acuitas Therapeutics to develop gene therapy delivery systems for age-related diseases. 该协议是非稀释性,并由Acuitas完全资助,他们将使用他们的脂质纳米粒子技术来制定Genflow的SIRT6mRNA有效载荷用于临床前评估. The agreement is non-dilutive and fully funded by Acuitas, who will use their lipid nanoparticle technology to formulate Genflow's SIRT6 mRNA payload for preclinical evaluation. 这次合作旨在验证SIRT6平台,并支持Genflow首选产品GF-1002的开发. This collaboration aims to validate the SIRT6 platform and support the development of Genflow's lead candidate, GF-1002.